Benigno Rodriguez

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/2268308/publications.pdf

Version: 2024-02-01

147 papers	15,197 citations	34105 52 h-index	18130 120 g-index
148 all docs	148 docs citations	148 times ranked	14563 citing authors

#	Article	IF	Citations
1	Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nature Medicine, 2006, 12, 1365-1371.	30.7	3,107
2	Effect of Early versus Deferred Antiretroviral Therapy for HIV on Survival. New England Journal of Medicine, 2009, 360, 1815-1826.	27.0	986
3	Plasma Levels of Bacterial DNA Correlate with Immune Activation and the Magnitude of Immune Restoration in Persons with Antiretroviralâ€Treated HIV Infection. Journal of Infectious Diseases, 2009, 199, 1177-1185.	4.0	527
4	Soluble Markers of Inflammation and Coagulation but Not T-Cell Activation Predict Nonâ€“AIDS-Defining Morbid Events During Suppressive Antiretroviral Treatment. Journal of Infectious Diseases, 2014, 210, 1248-1259.	4.0	464
5	Risk of Anal Cancer in HIV-Infected and HIV-Uninfected Individuals in North America. Clinical Infectious Diseases, 2012, 54, 1026-1034.	5.8	453
6	Gut Epithelial Barrier Dysfunction and Innate Immune Activation Predict Mortality in Treated HIV Infection. Journal of Infectious Diseases, 2014, 210, 1228-1238.	4.0	395
7	Prevention of Vaginal SHIV Transmission in Rhesus Macaques Through Inhibition of CCR5. Science, 2004, 306, 485-487.	12.6	364
8	Incomplete Peripheral CD4⁺Cell Count Restoration in HIVâ€Infected Patients Receiving Longâ€Term Antiretroviral Treatment. Clinical Infectious Diseases, 2009, 48, 787-794.	5.8	329
9	Impact of combination antiretroviral therapy on cerebrospinal fluid HIV RNA and neurocognitive performance. Aids, 2009, 23, 1359-1366.	2.2	305
10	Predictive Value of Plasma HIV RNA Level on Rate of CD4 T-Cell Decline in Untreated HIV Infection. JAMA - Journal of the American Medical Association, 2006, 296, 1498.	7.4	288
11	Perforin Expression Directly Ex Vivo by HIV-Specific CD8+ T-Cells Is a Correlate of HIV Elite Control. PLoS Pathogens, 2010, 6, e1000917.	4.7	284
12	Immunologic Failure Despite Suppressive Antiretroviral Therapy Is Related to Activation and Turnover of Memory CD4 Cells. Journal of Infectious Diseases, 2011, 204, 1217-1226.	4.0	265
13	Cohort profile: the Centers for AIDS Research Network of Integrated Clinical Systems. International Journal of Epidemiology, 2008, 37, 948-955.	1.9	242
14	Increased tissue factor expression on circulating monocytes in chronic HIV infection: relationship to in vivo coagulation and immune activation. Blood, 2010, 115, 161-167.	1.4	241
15	Continued CD4 cell count increases in HIV-infected adults experiencing 4 years of viral suppression on antiretroviral therapy. Aids, 2003, 17, 1907-1915.	2.2	229
16	Effects of Recombinant Human Interleukin 7 on T-Cell Recovery and Thymic Output in HIV-Infected Patients Receiving Antiretroviral Therapy: Results of a Phase I/IIa Randomized, Placebo-Controlled, Multicenter Study. Clinical Infectious Diseases, 2012, 55, 291-300.	5.8	209
17	Incomplete Reconstitution of T Cell Subsets on Combination Antiretroviral Therapy in the AIDS Clinical Trials Group Protocol 384. Clinical Infectious Diseases, 2009, 48, 350-361.	5.8	202
18	Shared monocyte subset phenotypes in HIV-1 infection and in uninfected subjects with acute coronary syndrome. Blood, 2012, 120, 4599-4608.	1.4	188

#	Article	IF	Citations
19	Predictive Accuracy of the Veterans Aging Cohort Study Index for Mortality With HIV Infection. Journal of Acquired Immune Deficiency Syndromes (1999), 2013, 62, 149-163.	2.1	188
20	Late Presentation for Human Immunodeficiency Virus Care in the United States and Canada. Clinical Infectious Diseases, 2010, 50, 1512-1520.	5.8	187
21	HIV Type 1 Chemokine Coreceptor Use among Antiretroviral-Experienced Patients Screened for a Clinical Trial of a CCR5 Inhibitor: AIDS Clinical Trial Group A5211. Clinical Infectious Diseases, 2007, 44, 591-595.	5.8	179
22	Cohort Profile: The North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD). International Journal of Epidemiology, 2007, 36, 294-301.	1.9	176
23	Abnormal activation and cytokine spectra in lymph nodes of people chronically infected with HIV-1. Blood, 2007, 109, 4272-4279.	1.4	175
24	Temporal Trends in Presentation and Survival for HIV-Associated Lymphoma in the Antiretroviral Therapy Era. Journal of the National Cancer Institute, 2013, 105, 1221-1229.	6.3	152
25	Effect of Baseline- and Treatment-Related Factors on Immunologic Recovery After Initiation of Antiretroviral Therapy in HIV-1-Positive Subjects. Journal of Acquired Immune Deficiency Syndromes (1999), 2006, 42, 426-434.	2.1	148
26	Interferon-Î± Is the Primary Plasma Type-I IFN in HIV-1 Infection and Correlates with Immune Activation and Disease Markers. PLoS ONE, 2013, 8, e56527.	2.5	146
27	Prevalence and Predictors of Substance Use Disorders Among HIV Care Enrollees in the United States. AIDS and Behavior, 2017, 21, 1138-1148.	2.7	145
28	End-Stage Renal Disease Among HIV-Infected Adults in North America. Clinical Infectious Diseases, 2015, 60, 941-949.	5.8	142
29	TLR9 stimulation drives naÃ¯ve B cells to proliferate and to attain enhanced antigen presenting function. European Journal of Immunology, 2007, 37, 2205-2213.	2.9	132
30	Increased Platelet and Microparticle Activation in HIV Infection. Journal of Acquired Immune Deficiency Syndromes (1999), 2012, 59, 340-346.	2.1	131
31	Multimorbidity Among Persons Living with Human Immunodeficiency Virus in the United States. Clinical Infectious Diseases, 2018, 66, 1230-1238.	5.8	131
32	Pretreatment Levels of Soluble Cellular Receptors and Interleukinâ€6 Are Associated with HIV Disease Progression in Subjects Treated with Highly Active Antiretroviral Therapy. Journal of Infectious Diseases, 2010, 201, 1796-1805.	4.0	124
33	Characterizing HIV Transmission Networks Across the United States. Clinical Infectious Diseases, 2012, 55, 1135-1143.	5.8	120
34	Toll-Like Receptor Ligands Induce Human T Cell Activation and Death, a Model for HIV Pathogenesis. PLoS ONE, 2008, 3, e1915.	2.5	120
35	The immunologic effects of maraviroc intensification in treated HIV-infected individuals with incomplete CD4+ T-cell recovery: a randomized trial. Blood, 2013, 121, 4635-4646.	1.4	117
36	CD8 T-Cell Expansion and Inflammation Linked to CMV Coinfection in ART-treated HIV Infection. Clinical Infectious Diseases, 2016, 62, 392-396.	5.8	114

#	Article	IF	Citations
37	Risk factors for chronic kidney disease in a large cohort of HIV-1 infected individuals initiating antiretroviral therapy in routine care. Aids, 2012, 26, 1907-1915.	2.2	111
38	Incidence and Timing of Cancer in HIV-Infected Individuals Following Initiation of Combination Antiretroviral Therapy. Clinical Infectious Diseases, 2013, 57, 756-764.	5.8	107
39	Safety, pharmacokinetics, and immunological activities of multiple intravenous or subcutaneous doses of an anti-HIV monoclonal antibody, VRC01, administered to HIV-uninfected adults: Results of a phase 1 randomized trial. PLoS Medicine, 2017, 14, e1002435.	8.4	104
40	IL-15 promotes activation and expansion of CD8+ T cells in HIV-1 infection. Journal of Clinical Investigation, 2016, 126, 2745-2756.	8.2	97
41	HIV Viral Suppression Trends Over Time Among HIV-Infected Patients Receiving Care in the United States, 1997 to 2015. Annals of Internal Medicine, 2018, 169, 376.	3.9	91
42	Trends and Disparities in Antiretroviral Therapy Initiation and Virologic Suppression Among Newly Treatment-Eligible HIV-Infected Individuals in North America, 2001â€“2009. Clinical Infectious Diseases, 2013, 56, 1174-1182.	5.8	90
43	Oxidized LDL Levels Are Increased in HIV Infection and May Drive Monocyte Activation. Journal of Acquired Immune Deficiency Syndromes (1999), 2015, 69, 154-160.	2.1	85
44	Impact of NRTIs on lipid levels among a large HIV-infected cohort initiating antiretroviral therapy in clinical care. Aids, 2011, 25, 185-195.	2.2	81
45	Inflammatory Cytokines Drive CD4+ T-Cell Cycling and Impaired Responsiveness to Interleukin 7: Implications for Immune Failure in HIV Disease. Journal of Infectious Diseases, 2014, 210, 619-629.	4.0	77
46	Increased Levels of Human Beta-Defensins mRNA in Sexually HIV-1 Exposed But Uninfected Individuals. Current HIV Research, 2008, 6, 531-538.	0.5	74
47	CD4 count at presentation for HIV care in the United States and Canada: Are those over 50 years more likely to have a delayed presentation?. AIDS Research and Therapy, 2010, 7, 45.	1.7	73
48	TLR Ligand-Dependent Activation of Naive CD4 T Cells by Plasmacytoid Dendritic Cells Is Impaired in Hepatitis C Virus Infection. Journal of Immunology, 2007, 178, 4436-4444.	0.8	69
49	Cancer-Attributable Mortality Among People With Treated Human Immunodeficiency Virus Infection in North America. Clinical Infectious Diseases, 2017, 65, 636-643.	5.8	67
50	Cycling CD4+ T cells in HIV-infected immune nonresponders have mitochondrial dysfunction. Journal of Clinical Investigation, 2018, 128, 5083-5094.	8.2	67
51	HIV Pathogenesis: The Host. Cold Spring Harbor Perspectives in Medicine, 2012, 2, a007005-a007005.	6.2	63
52	Inflammation Perturbs the IL-7 Axis, Promoting Senescence and Exhaustion that Broadly Characterize Immune Failure in Treated HIV Infection. Journal of Acquired Immune Deficiency Syndromes (1999), 2016, 71, 483-492.	2.1	59
53	Trends in Multidrug Treatment Failure and Subsequent Mortality among Antiretroviral Therapyâ€“Experienced Patients with HIV Infection in North America. Clinical Infectious Diseases, 2009, 49, 1582-1590.	5.8	55
54	Lymphoid tissue fibrosis is associated with impaired vaccine responses. Journal of Clinical Investigation, 2018, 128, 2763-2773.	8.2	55

#	Article	IF	Citations
55	Peripheral Blood B Cell Subset Skewing Is Associated with Altered Cell Cycling and Intrinsic Resistance to Apoptosis and Reflects a State of Immune Activation in Chronic Hepatitis C Virus Infection. Journal of Immunology, 2010, 185, 3019-3027.	0.8	52
56	Safety, Tolerability, and Immunogenicity of Repeated Doses of DermaVir, a Candidate Therapeutic HIV Vaccine, in HIV-Infected Patients Receiving Combination Antiretroviral Therapy. Journal of Acquired Immune Deficiency Syndromes (1999), 2013, 64, 351-359.	2.1	52
57	High Levels of Antiretroviral Use and Viral Suppression Among Persons in HIV Care in the United States, 2010. Journal of Acquired Immune Deficiency Syndromes (1999), 2013, 63, 299-306.	2.1	51
58	Effect of the CCR5 antagonist maraviroc on the occurrence of immune reconstitution inflammatory syndrome in HIV (CADIRIS): a double-blind, randomised, placebo-controlled trial. Lancet HIV,the, 2014, 1, e60-e67.	4.7	51
59	Determinants of Protection among HIVâ€Exposed Seronegative Persons: An Overview. Journal of Infectious Diseases, 2010, 202, S333-S338.	4.0	49
60	Reduced Naive CD4 T Cell Numbers and Impaired Induction of CD27 in Response to T Cell Receptor Stimulation Reflect a State of Immune Activation in Chronic Hepatitis C Virus Infection. Journal of Infectious Diseases, 2011, 203, 635-645.	4.0	49
61	Plasma levels of B-lymphocyte stimulator increase with HIV disease progression. Aids, 2003, 17, 1983-1985.	2.2	46
62	Association of immunosuppression and HIV viraemia with non-Hodgkin lymphoma risk overall and by subtype in people living with HIV in Canada and the USA: a multicentre cohort study. Lancet HIV,the, 2019, 6, e240-e249.	4.7	46
63	Dynamics of Immune Reconstitution and Activation Markers in HIV+ Treatment-NaÃ¯ve Patients Treated with Raltegravir, Tenofovir Disoproxil Fumarate and Emtricitabine. PLoS ONE, 2013, 8, e83514.	2.5	45
64	Comparison of Kaposi Sarcoma Risk in Human Immunodeficiency Virus-Positive Adults Across 5 Continents: A Multiregional Multicohort Study. Clinical Infectious Diseases, 2017, 65, 1316-1326.	5.8	44
65	Hepatitis C Viremia and the Risk of Chronic Kidney Disease in HIV-Infected Individuals. Journal of Infectious Diseases, 2013, 208, 1240-1249.	4.0	43
66	Poorly Controlled HIV Infection: An Independent Risk Factor for Liver Fibrosis. Journal of Acquired Immune Deficiency Syndromes (1999), 2016, 72, 437-443.	2.1	43
67	Using observational data to emulate a randomized trial of dynamic treatment-switching strategies: an application to antiretroviral therapy. International Journal of Epidemiology, 2016, 45, 2038-2049.	1.9	43
68	Peripheral Sâ€Phase T Cells in HIV Disease Have a Central Memory Phenotype and Rarely Have Evidence of Recent T Cell Receptor Engagement. Journal of Infectious Diseases, 2005, 192, 62-70.	4.0	42
69	Interferon-Alpha Administration Enhances CD8+ T Cell Activation in HIV Infection. PLoS ONE, 2012, 7, e30306.	2.5	42
70	Desensitization to type I interferon in HIV-1 infection correlates with markers of immune activation and disease progression. Blood, 2009, 113, 5497-5505.	1.4	41
71	Cyclosporin A Provides No Sustained Immunologic Benefit to Persons with Chronic HIVâ€1 Infection Starting Suppressive Antiretroviral Therapy: Results of a Randomized, Controlled Trial of the AIDS Clinical Trials Group A5138. Journal of Infectious Diseases, 2006, 194, 1677-1685.	4.0	39
72	HIV Viremia and Incidence of Non-Hodgkin Lymphoma in Patients Successfully Treated With Antiretroviral Therapy. Clinical Infectious Diseases, 2014, 58, 1599-1606.	5.8	39

#	Article	IF	Citations
73	Effect of GB Virus C Coinfection on Response to Antiretroviral Treatment in Human Immunodeficiency Virusâ€"Infected Patients. Journal of Infectious Diseases, 2003, 187, 504-507.	4.0	38
74	Impaired Monocyte Maturation in Response to CpG Oligodeoxynucleotide Is Related to Viral RNA Levels in Human Immunodeficiency Virus Disease and Is at Least Partially Mediated by Deficiencies in Alpha/Beta Interferon Responsiveness and Production. Journal of Virology, 2005, 79, 4109-4119.	3.4	37
75	Impaired Plasmacytoid Dendritic Cell (PDC)-NK Cell Activity in Viremic Human Immunodeficiency Virus Infection Attributable to Impairments in both PDC and NK Cell Function. Journal of Virology, 2009, 83, 11175-11187.	3.4	37
76	Prospective Analysis of Lipid Composition Changes with Antiretroviral Therapy and Immune Activation in Persons Living with HIV. Pathogens and Immunity, 2017, 2, 376.	3.1	36
77	Lymphoma Immune Reconstitution Inflammatory Syndrome in the Center for AIDS Research Network of Integrated Clinical Systems Cohort. Clinical Infectious Diseases, 2014, 59, 279-286.	5.8	35
78	Translocated microbiome composition determines immunological outcome in treated HIV infection. Cell, 2021, 184, 3899-3914.e16.	28.9	35
79	Interferon-Î± differentially rescues CD4 and CD8 T cells from apoptosis in HIV infection. Aids, 2006, 20, 1379-1389.	2.2	34
80	Impaired Naive and Memory B-Cell Responsiveness to TLR9 Stimulation in Human Immunodeficiency Virus Infection. Journal of Virology, 2008, 82, 7837-7845.	3.4	34
81	Risk Factors for Tuberculosis After Highly Active Antiretroviral Therapy Initiation in the United States and Canada: Implications for Tuberculosis Screening. Journal of Infectious Diseases, 2011, 204, 893-901.	4.0	33
82	Association of early HIV viremia with mortality after HIV-associated lymphoma. Aids, 2013, 27, 2365-2373.	2.2	33
83	Treatment failure and drug resistance is more frequent in HIV-1 subtype D versus subtype A-infected Ugandans over a 10-year study period. Aids, 2013, 27, 1899-1909.	2.2	33
84	During Hepatitis C Virus (HCV) Infection and HCV-HIV Coinfection, an Elevated Plasma Level of Autotaxin Is Associated With Lysophosphatidic Acid and Markers of Immune Activation That Normalize During Interferon-Free HCV Therapy. Journal of Infectious Diseases, 2016, 214, 1438-1448.	4.0	33
85	Impaired T-cell responses to sphingosine-1-phosphate in HIV-1 infected lymph nodes. Blood, 2013, 121, 2914-2922.	1.4	31
86	HIV-1 Is Not a Major Driver of Increased Plasma IL-6 Levels in Chronic HIV-1 Disease. Journal of Acquired Immune Deficiency Syndromes (1999), 2012, 61, 145-152.	2.1	30
87	Influence of Substance Use Disorders on 2-Year HIV Care Retention in the United States. AIDS and Behavior, 2018, 22, 742-751.	2.7	30
88	Differential Effects of Hepatitis C Virus JFH1 on Human Myeloid and Plasmacytoid Dendritic Cells. Journal of Virology, 2009, 83, 5693-5707.	3.4	29
89	Changes in Inflammation but Not in T-Cell Activation Precede Non-AIDS-Defining Events in a Case-Control Study of Patients on Long-term Antiretroviral Therapy. Journal of Infectious Diseases, 2018, 218, 239-248.	4.0	29
90	Transmitted Drug Resistance in the CFAR Network of Integrated Clinical Systems Cohort: Prevalence and Effects on Pre-Therapy CD4 and Viral Load. PLoS ONE, 2011, 6, e21189.	2.5	28

#	Article	IF	Citations
91	Association of Immunosuppression and Human Immunodeficiency Virus (HIV) Viremia With Anal Cancer Risk in Persons Living With HIV in the United States and Canada. Clinical Infectious Diseases, 2020, 70, 1176-1185.	5.8	27
92	Systemic Immune Activation in HIV Infection Is Associated with Decreased MDC Responsiveness to TLR Ligand and Inability to Activate Naive CD4 T-Cells. PLoS ONE, 2011, 6, e23884.	2.5	23
93	Novel Method for Simultaneous Quantification of Phenotypic Resistance to Maturation, Protease, Reverse Transcriptase, and Integrase HIV Inhibitors Based on 3â€²Gag(p2/p7/p1/p6)/PR/RT/INT-Recombinant Viruses: a Useful Tool in the Multitarget Era of Antiretroviral Therapy. Antimicrobial Agents and Chemotherapy, 2011, 55, 3729-3742.	3.2	23
94	Factors Associated With Delayed Hepatitis B Viral Suppression on Tenofovir Among Patients Coinfected With HBV-HIV in the CNICS Cohort. Journal of Acquired Immune Deficiency Syndromes (1999), 2014, 66, 96-101.	2.1	23
95	A Family Cluster of Five Cases of Group A Streptococcal Pneumonia. Pediatrics, 2003, 112, e61-e65.	2.1	22
96	Dissecting the T Cell Response: Proliferation Assays vs. Cytokine Signatures by ELISPOT. Cells, 2012, 1, 127-140.	4.1	21
97	Physical Activity Intensity is Associated with Symptom Distress in the CNICS Cohort. AIDS and Behavior, 2019, 23, 627-635.	2.7	21
98	Persistent Replication of Human Immunodeficiency Virus Type 1 despite Treatment of Pulmonary Tuberculosis in Dually Infected Subjects. Vaccine Journal, 2005, 12, 1298-1304.	3.1	20
99	Current Practices of Screening for Incident Hepatitis C Virus (HCV) Infection Among HIV-Infected, HCV-Uninfected Individuals in Primary Care. Clinical Infectious Diseases, 2014, 59, 1686-1693.	5.8	19
100	Pre-vaccine plasma levels of soluble inflammatory indices negatively predict responses to HAV, HBV, and tetanus vaccines in HCV and HIV infection. Vaccine, 2018, 36, 453-460.	3.8	19
101	"Inflammescent" CX3CR1+CD57+ CD8 T cells are generated and expanded by IL-15. JCI Insight, 2020, 5, .	5.0	18
102	A Prospective Cohort Study of Periodontal Disease Measures and Cardiovascular Disease Markers in HIV-Infected Adults. AIDS Research and Human Retroviruses, 2011, 27, 1157-1166.	1.1	16
103	Baseline Levels of Soluble CD14 and CD16+56â˜ Natural Killer Cells Are Negatively Associated With Response to Interferon/Ribavirin Therapy During HCV-HIV-1 Coinfection. Journal of Infectious Diseases, 2012, 206, 969-973.	4.0	16
104	Substantial decline in heavily treated therapy-experienced persons with HIV with limited antiretroviral treatment options. Aids, 2020, 34, 2051-2059.	2.2	16
105	HIV Coinfection Impairs CD28â€Mediated Costimulation of Hepatitis C Virusâ€“Specific CD8 Cells. Journal of Infectious Diseases, 2006, 194, 391-400.	4.0	15
106	Bacterial Colonization and Beta Defensins in the Female Genital Tract in HIV Infection. Current HIV Research, 2012, 10, 504-512.	0.5	15
107	Plasma Proteome Analysis Reveals Overlapping, yet Distinct Mechanisms of Immune Activation in Chronic HCV and HIV Infections. Journal of Acquired Immune Deficiency Syndromes (1999), 2013, 63, 563-571.	2.1	15
108	Effectiveness of Direct-Acting Antiviral Therapy in Patients With Human Immunodeficiency Virusâ€“Hepatitis C Virus Coinfection in Routine Clinical Care: A Multicenter Study. Open Forum Infectious Diseases, 2019, 6, ofz100.	0.9	15

#	Article	IF	Citations
109	Physical activity trends and metabolic health outcomes in people living with HIV in the US, 2008â€“2015. Progress in Cardiovascular Diseases, 2020, 63, 170-177.	3.1	15
110	Gender differences in human immunodeficiency virus (HIV) RNA and CD4 cell counts among new entrants to HIV care. Clinical Microbiology and Infection, 2006, 12, 389-391.	6.0	14
111	Markers of T Cell Exhaustion and Senescence and Their Relationship to Plasma TGF-Î² Levels in Treated HIV+ Immune Non-responders. Frontiers in Immunology, 2021, 12, 638010.	4.8	14
112	Statins Blunt HAART-Induced CD4 T-Cell Gains but Have No Long-Term Effect on Virologic Response to HAART. Journal of the International Association of Providers of AIDS Care, 2007, 6, 198-202.	1.2	13
113	One Size Fits (n)One: The Influence of Sex, Age, and Sexual Human Immunodeficiency Virus (HIV) Acquisition Risk on Racial/Ethnic Disparities in the HIV Care Continuum in the United States. Clinical Infectious Diseases, 2019, 68, 795-802.	5.8	13
114	Effect of Nadir CD4+ T Cell Count on Clinical Measures of Periodontal Disease in HIV+ Adults before and during Immune Reconstitution on HAART. PLoS ONE, 2013, 8, e76986.	2.5	13
115	Gut-derived bacterial toxins impair memory CD4+ T cell mitochondrial function in HIV-1 infection. Journal of Clinical Investigation, 2022, 132, .	8.2	13
116	Randomized Study of Dual Versus Single Ritonavir-Enhanced Protease Inhibitors for Protease Inhibitor-Experienced Patients with HIV. HIV Clinical Trials, 2008, 9, 91-102.	2.0	12
117	Disseminated Mycobacterium chelonae Infection in a Patient Receiving an Epidermal Growth Factor Receptor Inhibitor for Advanced Head and Neck Cancer. Journal of Clinical Microbiology, 2012, 50, 194-195.	3.9	12
118	Identifying HIV care enrollees at-risk for cannabis use disorder. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 2017, 29, 846-850.	1.2	12
119	Virologic Failure Among People Living With HIV Initiating Dolutegravir-Based Versus Other Recommended Regimens in Real-World Clinical Care Settings. Journal of Acquired Immune Deficiency Syndromes (1999), 2019, 81, 572-577.	2.1	12
120	Hospitalization Rates and Causes Among Persons With HIV in the United States and Canada, 2005â€“2015. Journal of Infectious Diseases, 2021, 223, 2113-2123.	4.0	12
121	Chemokine (C-C Motif) Receptor 5 â^'2459 Genotype in Patients Receiving Highly Active Antiretroviral Therapy: Race-Specific Influence on Virologic Success. Journal of Infectious Diseases, 2011, 204, 291-298.	4.0	10
122	Monitoring clinical trials of therapeutic vaccines in HIV infection: role of treatment interruption. Current Opinion in HIV and AIDS, 2007, 2, 56-61.	3.8	9
123	Accessory cell dependent NK cell mediated PBMC IFN-Î³ production is defective in HIV infection. Clinical Immunology, 2009, 131, 288-297.	3.2	9
124	Missing Data on the Estimation of the Prevalence of Accumulated Human Immunodeficiency Virus Drug Resistance in Patients Treated With Antiretroviral Drugs in North America. American Journal of Epidemiology, 2011, 174, 727-735.	3.4	9
125	Association between U.S. State AIDS Drug Assistance Program (ADAP) Features and HIV Antiretroviral Therapy Initiation, 2001â€“2009. PLoS ONE, 2013, 8, e78952.	2.5	9
126	Identification of Occult Fusobacterium nucleatum Central Nervous System Infection by Use of PCR-Electrospray Ionization Mass Spectrometry. Journal of Clinical Microbiology, 2014, 52, 3462-3464.	3.9	9

#	Article	IF	Citations
127	Impaired human immunodeficiency virus type 1 replicative fitness in atypical viremic non-progressor individuals. AIDS Research and Therapy, 2017, 14, 15.	1.7	9
128	In vitro naÃ¯ve T cell proliferation failure predicts poor post-immunization responses to neoantigen, but not recall antigens, in HIV-infection. Clinical Immunology, 2010, 136, 400-408.	3.2	8
129	Genetically Associated CD16+56â^' Natural Killer Cell Interferon (IFN)â€"Î±R Expression Regulates Signaling and Is Implicated in IFN-Î±â€"Induced Hepatitis C Virus Decline. Journal of Infectious Diseases, 2012, 205, 1131-1141.	4.0	8
130	Can immune-related genotypes illuminate the immunopathogenesis of cytomegalovirus disease in human immunodeficiency virusâ€"infected patients?. Human Immunology, 2012, 73, 168-174.	2.4	8
131	Natural Cytotoxicity Receptorâ€"Dependent Natural Killer Cytolytic activity Directed at Hepatitis C Virus (HCV) Is Associated With Liver Inflammation, African American Race, IL28B Genotype, and Response to Pegylated Interferon/Ribavirin Therapy in Chronic HCV Infection. Journal of Infectious Diseases, 2014, 209, 1591-1601.	4.0	8
132	The PROSPER-HIV Study: A Research Protocol to Examine Relationships Among Physical Activity, Diet Intake, and Symptoms in Adults Living With HIV. Journal of the Association of Nurses in AIDS Care, 2020, 31, 346-352.	1.0	8
133	CD4 Count at Entry into Care and at Antiretroviral Therapy Prescription among Adults with Human Immunodeficiency Virus in the United States, 2005-2018. Clinical Infectious Diseases, 2021, 73, e2334-e2337.	5.8	8
134	Hepatitis C Virus-Specific T-Cell Gamma Interferon and Proliferative Responses Are More Common in Perihepatic Lymph Nodes than in Peripheral Blood or Liver. Journal of Virology, 2008, 82, 11742-11748.	3.4	7
135	Genetic variations in loci relevant to natural killer cell function are affected by ethnicity but are generally not correlated with susceptibility to HIVâ€1. Tissue Antigens, 2012, 79, 367-371.	1.0	7
136	Comparative description of haplotype structure and genetic diversity of MDR1 (ABCB1) in HIV-positive and HIV-negative populations. Infection, Genetics and Evolution, 2010, 10, 60-67.	2.3	6
137	African Ancestry Influences CCR5 â^'2459G>A Genotype-Associated Virologic Success of Highly Active Antiretroviral Therapy. Journal of Acquired Immune Deficiency Syndromes (1999), 2014, 66, 102-107.	2.1	6
138	Frequencies of FoxP3+ naÃ¯ve T cells are related to both viral load and naÃ¯ve T cell proliferation responses in HIV disease. Journal of Leukocyte Biology, 2011, 90, 621-628.	3.3	4
139	Antiretroviral drug class and anaemia risk in the current treatment era among people living with HIV in the USA: a clinical cohort study. BMJ Open, 2020, 10, e031487.	1.9	4
140	Current and Past Immunodeficiency Are Associated With Higher Hospitalization Rates Among Persons on Virologically Suppressive Antiretroviral Therapy for up to 11 Years. Journal of Infectious Diseases, 2021, 224, 657-666.	4.0	3
141	Immunologic Effects of Maraviroc in HIV-Infected Patients with Severe CD4 Lymphopenia Starting Antiretroviral Therapy: A Sub-Study of the CADIRIS Trial. Pathogens and Immunity, 2017, 2, 151.	3.1	3
142	New Entrants to HIV Care Are Presenting Only at Marginally Earlier Stages of Disease but May Increasingly Represent Groups Perceived at Lower Risk. Journal of the International Association of Providers of AIDS Care, 2005, 4, 47-51.	1.2	2
143	Differentiation of Type 1 and Type 2 Myocardial Infarctions Among HIV-Infected Patients Requires Adjudication Due to Overlap in Risk Factors. AIDS Research and Human Retroviruses, 2018, 34, 916-921.	1.1	2
144	Presenting Plasma HIV RNA Level and Rate of CD4 T-Cell Declineâ€"Reply. JAMA - Journal of the American Medical Association, 2007, 297, 805.	7.4	0

#	Article	IF	Citations
145	S03-06 OA. Rapid perforin upregulation by CD8 T cells in elite controllers as a correlate of immune-mediated control of HIV replication. Retrovirology, 2009, 6, .	2.0	0
146	Stability of plasma indices of inflammation/coagulation and homeostasis after fatty and non-fatty meals in treated people with HIV. Journal of Virus Eradication, 2019, 5, 28-32.	0.5	0
147	Stability of plasma indices of inflammation/coagulation and homeostasis after fatty and non-fatty meals in treated people with HIV. Journal of Virus Eradication, 2019, 5, 28-32.	0.5	0